Picard Medical, Inc. (NYSE: PMI)

Picard Medical, Inc. is a medical technology company that designs, manufactures, and markets mechanical circulatory support systems for patients with advanced heart failure. The company's primary product is the SynCardia Total Artificial Heart (TAH), a fully implantable device that replaces both ventricles of the human heart and is used as a bridge to heart transplantation. Picard Medical operates as a holding company, with all business activities conducted through its wholly owned subsidiary, SynCardia Systems, LLC.

Picard Medical generates revenue primarily through the sale of the SynCardia TAH system, which includes the implantable artificial ventricles, external pneumatic drivers such as the Companion 2 Driver and the Freedom Driver, and associated components like drivelines. The company receives reimbursement for implant procedures through hospital billing systems, with procedures covered under Medicare Diagnosis Related Group 001, the highest reimbursement tier for cardiac surgeries. Revenue is derived from hospitals and medical centers that perform implant procedures on patients with end-stage biventricular heart failure.

The company operates through the following segments: SynCardia Total Artificial Heart

• SynCardia Total Artificial Heart: This segment encompasses the design, manufacturing, and commercialization of the SynCardia TAH system, which includes the 50cc and 70cc implantable ventricular units, the Companion 2 (C2) Driver for hospital use, and the Freedom Driver for ambulatory patient support. The system provides pulsatile blood flow by replacing both heart ventricles and all four heart valves, enabling patients to maintain circulation while awaiting transplantation. The SynCardia TAH is the only total artificial heart approved for commercial use by the U. S. Food and Drug Administration and Health Canada.

• SynCardia Total Artificial Heart: The segment also supports the development of next-generation technologies, including the Emperor TAH, a fully implantable device intended to eliminate the need for external drivers, and the Unicorn driver, a next-generation pneumatic system designed to improve portability, reduce size and weight, and enhance patient mobility. Both the Emperor TAH and Unicorn driver are currently in preclinical and clinical development stages, with regulatory approval timelines subject to FDA review processes.

Picard Medical holds a leading position in the total artificial heart market, being the only company with FDA and Health Canada-approved devices for commercial use in the United States and Canada. While competitors such as CARMAT SA and BiVACOR Inc are developing alternative total artificial heart systems, none have received equivalent regulatory approvals for widespread commercial use. Picard’s competitive advantages stem from over 30 years of clinical experience, more than 2,100 cumulative implantations globally, proprietary manufacturing processes for its Segmented Polyurethane Solution material, and established relationships with certified implanting centers across North America and select international markets.

Picard Medical serves advanced heart failure patients requiring mechanical circulatory support, primarily through hospitals and specialized heart transplant centers that perform implantation procedures. The company’s customers include major medical institutions such as Cedars-Sinai Medical Center and other high-volume transplant centers in the United States, where clinical outcomes and long-term survival data have been documented in peer-reviewed studies. These centers rely on the SynCardia TAH as a bridge to transplantation for patients ineligible for or awaiting donor hearts.